1. Market Research
  2. > Pathology
Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

About 7000 reports for Lymphoma (page 346)

Purchase Reports From Reputable Market Research Publishers

Plunkett’s Advertising & Branding Industry Almanac 2017: Advertising & Branding Industry Market Research, Statistics, Trends & Leading Companies

  • $ 350
  • March 2017
  • 487 pages

Epsilon has worked with customers such as Southwest Indian Foundation, Cord Blood Registry, Hormel, ## by Whole Foods Market, The Nature Conservancy, National Wildlife Federation, Leukemia & Lymphoma Society, Norwegian Cruise Line and many more.

  • Advertising
  • Advertising And Marketing
  • Lymphoma
  • Media And Entertainment
  • Company

Compugen Ltd. - Product Pipeline Review - 2016

  • $ 1500
  • April 2016
  • 48 pages

The candidate also showed expression in other malignancies such as melanoma and lymphoma.

  • Lymphoma
  • Monoclonal Antibody
  • China
  • Company Operations
  • Compugen Ltd.

EntreMed, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 41 pages

INVESTMENTS Vendor, acquirer, target and partner report for CASI Pharmaceuticals, Inc.

  • Lymphoma
  • United States
  • Company
  • Corporate Finance
  • CASI Pharmaceuticals, Inc.

OSI Pharmaceuticals, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 91 pages

Vendor, acquirer, target and partner report for OSI Pharmaceuticals, Inc. and its subsidiaries.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • United States
  • OSI Pharmaceuticals, Inc.

Lorus Therapeutics, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 44 pages

Vendor, acquirer, target and partner report for Lorus Therapeutics, Inc. and its subsidiaries.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Corporate Finance
  • Lorus Therapeutics Inc.

Clinical Data, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 156 pages

Lymphomas--> Hodgkin' s Lymphoma Country Website Parent company Company type Business description Industry Address ## Brookline Avenue The Harvard University Parent company Company type Business description Industry Address City State Country Website Phone number Harvard Medical Scho

  • Clinical Research
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • CLINICAL DATA, INC.

Fatty Liver Disease Global Clinical Trials Review, H1, 2016

  • $ 2500
  • February 2016
  • 246 pages

Lymphoma Kinase Receptor or CD## Antigen or Mutant Anaplastic Lymphoma Kinase or EC ##. ##. ##. ##), C-Reactive Protein (Pentraxin ## or CRP), Tumor Necrosis Factor Alpha (TNF-Alpha or Cachectin)) Completed Phase II Interventional Bergamot University of Colorado ## Sep 2011 ## Sep 2013 ##

  • Clinical Trial
  • Digestive System Disorder
  • Drug Development
  • Pathology
  • Therapy

Actelion Ltd - Product Pipeline Review - 2016

  • $ 1500
  • March 2016
  • 74 pages

Actelion Ltd - Product Pipeline Review - 2016 Reference Code: GMDHC##CDB Publication Date: MAR 2016 © Global Markets Direct.

  • Lymphoma
  • Research And Development
  • Therapy
  • United States
  • Actelion Ltd

Global Radiopharmaceuticals Market Insight

  • $ 2200
  • February 2014
  • 450 pages

It is expected that over the next ##-## years horizon, this market would witness a steep increase owing to the introduction of many new products for treating lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer and other persistent cancers.

  • Cancer
  • Lymphoma
  • United States
  • World

Morphotek, Inc. - Product Pipeline Review - 2016

  • $ 1500
  • March 2016
  • 41 pages

The drug candidate is in Phase I stage of development for the treatment of recurrent or refractory solid tumors or lymphoma in pediatric patients.

  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States
  • Morphotek, Inc.

Infinity Pharmaceuticals, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 48 pages

Vendor, acquirer, target and partner report for Infinity Pharmaceuticals, Inc. and its subsidiaries.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Corporate Finance
  • Infinity Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 52 pages

Vendor, acquirer, target and partner report for Lexicon Pharmaceuticals, Inc. and its subsidiaries.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Corporate Finance
  • Lexicon Pharmaceuticals, Inc.

4SC AG – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 56 pages

Vendor, acquirer, target and partner report for ##SC AG and its subsidiaries.

  • Lymphoma
  • Pharmaceutical
  • Germany
  • Corporate Finance
  • 4SC AG

Phylogica Limited – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 55 pages

Vendor, acquirer, target and partner report for Phylogica Limited and its subsidiaries.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Corporate Finance
  • Phylogica Limited

Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Review, H1 2016

  • $ 2000
  • February 2016
  • 115 pages

It is in Phase I/ II for follicular lymphoma, indolent lymphoma, and mantle cell lymphoma and also in Phase I stage of development for relapsed or refractory B-cell malignancies such as diffuse large B-cell lymphoma, small lymphocytic lymphoma, follic

  • Immunotherapy
  • Lymphoma
  • Neurological Disorder
  • Pathology
  • Therapy

HUYA Bioscience International, LLC – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • June 2016
  • 63 pages

This trial is designed to assess safety, tolerability and antitumor activity of HBI-## in patients with advanced solid tumors and lymphomas.

  • Lymphoma
  • Pharmaceutical
  • China
  • Company
  • HUYA Bioscience International, LLC

Hyperlipidemia - Pipeline Review, H1 2016

  • $ 2000
  • February 2016
  • 212 pages

Hyperlipidemia - Pipeline Review, H## 2016 Reference Code: GMDHC##IDB Publication Date: February 2016 LIST OF TABLES Global Markets Direct' s, ' Hyperlipidemia - Pipeline Review, H## 2016', provides an overview of the Hyperlipidemia pipeline landscape.

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Lymphoma
  • Pharmaceutical
  • Therapy

Radient Pharmaceuticals Corporation (formerly AMDL, Inc.) – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 90 pages

lymphoma, and pancreatic cancers.

  • In Vitro Diagnostics
  • Lymphoma
  • Pharmaceutical
  • Corporate Finance
  • Radient Pharmaceuticals Corporation

AVEO Pharmaceuticals, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • March 2016
  • 93 pages

Biogen Idec is engaged in the discovery, development and commercialization of therapies for lymphoma, multiple sclerosis and rheumatoid arthritis.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Corporate Finance
  • AVEO Pharmaceuticals, Inc.
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on